Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

Table 4

Classification results from the LOOCV analysis*.

Patient ID	Response	LOOCV analysis
		True class	Classified as
1	2	SD + PR	SD + PR
2	3	PD	PD
3	1	SD + PR	SD + PR
4	2	SD + PR	SD + PR
5	2	SD + PR	SD + PR
6	3	PD	PD
7	2	SD + PR	SD + PR
8	1	SD + PR	SD + PR
9	1	SD + PR	SD + PR
10	2	SD + PR	SD + PR
11	2	SD + PR	SD + PR
12	3	PD	SD + PR
13	1	SD + PR	SD + PR
14	3	PD	SD + PR
15	1	SD + PR	SD + PR
16	3	PD	PD
17	2	SD + PR	SD + PR
18	2	SD + PR	PD

* Patient IDs given in bold are correctly classified with regards to response group in the analysis.